



WHO drug information.
v. 17, no. 2 (2003)
General Collection
W1 WH46
2003-09-17 08:31:07

WHO DRUG INFORMATION

VOLUME 17 • NUMBER 2 • 2003

RECOMMENDED INN LIST 49
INTERNATIONAL NONPROPRIETARY NAMES
FOR PHARMACEUTICAL SUBSTANCES



WORLD HEALTH ORGANIZATION • GENEVA

WHO DRUG INFORMATION

WHO Drug Information provides an overview of topics relating to drug development and regulation that are of current relevance and importance, and includes the lists of proposed and recommended International Nonproprietary Names for Pharmaceutical Substances (INN). Its contents reflect, but do not present, WHO policies and activities and they embrace socioeconomic as well as technical matters.

The objective is to bring issues that are of primary concern to drug regulators and pharmaceutical manufacturers to the attention of a wide audience of health professionals and policy-makers concerned with the rational use of drugs. In effect, the journal seeks to relate regulatory activity to therapeutic practice. It also aims to provide an open forum for debate. Invited contributions will portray a variety of viewpoints on matters of general policy with the aim of stimulating discussion not only in these columns but wherever relevant decisions on this subject have to be taken.

WHO Drug Information is published 4 times a year and can be ordered from: Marketing and Dissemination, World Health Organization, 1211 Geneva 27, Switzerland.

Annual subscription rate: Sw.fr. 75.— surface mail (other rates available)

Price per copy: Sw.fr. 25.—

(30% reduction in price for developing countries.)

***WHO Drug Information* can be viewed at:**

[http://www.who.int/drug information](http://www.who.int/drug_information)

© World Health Organization 2002

Publications of the World Health Organization enjoy copyright protection in accordance with the provisions of Protocol 2 of the Universal Copyright Convention. All rights reserved. For rights of reproduction or translation, in part or *in toto*, application should be made to: Coordinator, Publications, World Health Organization, 1211 Geneva 27, Switzerland. The World Health Organization welcomes such applications.

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the Secretariat of the World Health Organization concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries.

Authors alone are responsible for views expressed in signed contributions.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature which are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

ISSN 1010-9609

This material was copied
at the NLM and may be
Subject US Copyright Laws

WHO Drug Information

Contents

Good Manufacturing Practices

Implementation of good manufacturing practices 81

Personal Perspectives

Pharmacogenetics and existing therapies 84

Safety Issues

Fluticasone and adrenal crisis 92

Thiazolidinediones experience 92

Cefepime, ceftazidime and neurotoxicity 93

Interstitial nephritis and proton pump inhibitors 94

Interactions with grapefruit juice 95

Current Topics

New network for guideline development 96

Fake artesunate tablets circulating again 96

European Union enlargement: observers to EMEA 97

Clinical cancer research review 97

New foundation will develop tests for infectious diseases 98

TDR research training in 2004 99

Managing drug supply for primary health care 100

Latin American pharmacotherapy course 100

Regulatory and Safety Action

Gefitinib approved for lung cancer 102

New breath test for monitoring asthma 103

Risperidone: prescribing information update 103

Pan Pharmaceuticals product recalls 103

Telithromycine and myasthenia gravis 104

Astemizole: marketing suspension 105

Somatropin: negative opinion 105

Repaglinide and gemfibrozil: hazardous interaction 105

Adhesion prevention solution global withdrawal 105

Counterfeit Lipitor® 106

Paroxetine: avoid in children and adolescents 106

Aprepitant for nausea and vomiting during chemotherapy 107

Agalsidase beta approved 107

Imatinib mesylate approved for paediatric leukaemia 108

Drug-eluting stent for clogged heart arteries 108

Pegvisomant for acromegaly 109

Aspects of Quality Assurance

Fixed-combination medicines: an Australian perspective 110

Recent Publications and Sources of Information

International travel and health 113

Affordability of medicines 113

Drugs and money 113

ABPI launches online clinical trials register 114

Report of Expert Committee on Drug Dependence 114

Biomedical research in human subjects 114

Recommended International Nonproprietary Names: List 49 115

Drugs and money. Prices, affordability and cost containment. Available from: Marketing and Dissemination, World Health organization, 1211 Geneva 27, Switzerland. e-mail: bookorders@who.int

ABPI launches online clinical trials register

An online register of industry-sponsored clinical trials has been launched by the Association of the British Pharmaceutical Industry (ABPI). So far, the register includes details of 65 trials sponsored by five companies.

Since 2001, the ABPI has encouraged member companies to register clinical trials involving United Kingdom patients that form part of a licensing application for a new medicine. Participating countries are asked to register their phase III trials within three months of any product receiving its first licence in a major market. Ongoing trials can also be included.

Trial information listed on the website includes details of the sponsor company, design and methodology used, trial intervention method, planned and actual sample size, start and end date, and whether trial data have been published. Trial results are not given.

The website can be accessed through PJ Online at <http://www.pjonline.com/links> on a read-only basis.

Reference: *The Pharmaceutical Journal*, **270**: 640 (2003).

Expert Committee on Drug Dependence Report

The Thirty-third report presents recommendations from the Expert Committee on Drug Dependence which is responsible for reviewing information on dependence-producing drugs and assessing the need for international control by the UN Commission on Narcotic Drugs. It is important to balance the need for preventing diversion of therapeutic substances with abuse potential against the need to ensure access for therapeutic use. WHO has developed a formal procedure for its review of dependence-producing psychoactive substances which is described in the first part of the report.

This is followed by a critical review of five psychoactive substances (amfepramone, amineptine, buprenorphine, delta-9-tetrahydrocannabinol and tramadol). The report also discusses the substances that were pre-reviewed by the Committee, four of which (ketamine, zopiclone, butorphanol and khat) were recommended for critical review at a future meeting. The final section discusses the problems of the terminology used in reporting abuse-related adverse drug reactions and describes how confusion affects the reporting of adverse effects using as an example the selective serotonin reuptake inhibitors (SSRIs).

WHO Expert Committee on Drug Dependence. *Thirty-third report. WHO Technical Report Series, No. 915 (2003). Available from: Marketing and Dissemination, World Health organization, 1211 Geneva 27, Switzerland. e-mail: bookorders@who.int*

Biomedical research in human subjects

The Council for International Organizations of Medical Sciences (CIOMS) has published the revised International Ethical Guidelines for Biomedical Research Involving Human Subjects. This is the third revision of the guidelines, first issued in 1982, and consists of 21 core guidelines with commentaries. Appendices include the World Medical Association's Declaration of Helsinki.

The scope of the guidelines reflects the changes, advances and controversies that have characterized biomedical research ethics recently. The Guidelines are also designed to be of use in defining national policies on ethics, applying ethical standards and establishing or improving ethical review. A particular need is to consider the implications for research of the specific conditions and needs of different communities and countries.

International Ethical Guidelines for Biomedical Research Involving Human Subjects. Available from: Marketing and Dissemination, World Health organization, 1211 Geneva 27, Switzerland. e-mail: bookorders@who.int

International Nonproprietary Names for Pharmaceutical Substances (INN)

RECOMMENDED International Nonproprietary Names (Rec. INN): List 49

Notice is hereby given that, in accordance with paragraph 7 of the Procedure for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances [*Off. Rec. Wld Health Org.*, 1955, **60**, 3 (Resolution EB15.R7); 1969, **173**, 10 (Resolution EB43.R9)], the following names are selected as Recommended International Nonproprietary Names. The inclusion of a name in the lists of Recommended International Nonproprietary Names does not imply any recommendation of the use of the substance in medicine or pharmacy.

Lists of Proposed (1–85) and Recommended (1–45) International Nonproprietary Names can be found in *Cumulative List No. 10, 2002* (available in CD-ROM only).

Dénominations communes internationales des Substances pharmaceutiques (DCI)

Dénominations communes internationales RECOMMANDÉES (DCI Rec): Liste 49

Il est notifié que, conformément aux dispositions du paragraphe 7 de la Procédure à suivre en vue du choix de Dénominations communes internationales recommandées pour les Substances pharmaceutiques [*Actes off. Org. mond. Santé*, 1955, **60**, 3 (résolution EB15.R7); 1969, **173**, 10 (résolution EB43.R9)] les dénominations ci-dessous sont choisies par l'Organisation mondiale de la Santé en tant que dénominations communes internationales recommandées. L'inclusion d'une dénomination dans les listes de DCI recommandées n'implique aucune recommandation en vue de l'utilisation de la substance correspondante en médecine ou en pharmacie.

On trouvera d'autres listes de Dénominations communes internationales proposées (1–85) et recommandées (1–45) dans la *Liste récapitulative No. 10, 2002* (disponible sur CD-ROM seulement).

Denominaciones Comunes Internacionales para las Sustancias Farmacéuticas (DCI)

Denominaciones Comunes Internacionales RECOMENDADAS (DCI Rec.): Lista 49

De conformidad con lo que dispone el párrafo 7 del Procedimiento de Selección de Denominaciones Comunes Internacionales Recomendadas para las Sustancias Farmacéuticas [*Act. Of. Mund. Salud*, 1955, **60**, 3 (Resolución EB15.R7); 1969, **173**, 10 (Resolución EB43.R9)], se comunica por el presente anuncio que las denominaciones que a continuación se expresan han sido seleccionadas como Denominaciones Comunes Internacionales Recomendadas. La inclusión de una denominación en las listas de las Denominaciones Comunes Recomendadas no supone recomendación alguna en favor del empleo de la sustancia respectiva en medicina o en farmacia.

Las listas de Denominaciones Comunes Internacionales Propuestas (1–85) y Recomendadas (1–45) se encuentran reunidas en *Cumulative List No. 10, 2002* (disponible sólo en CD-ROM).

Latin, English, French, Spanish:

Recommended INN Chemical name or description; Molecular formula; Graphic formula

DCI Recommandée Nom chimique ou description; Formule brute; Formule développée

DCI Recomendada Nombre químico o descripción; Fórmula empírica; Fórmula desarrollada

albaconazolum

albaconazole

7-chloro-3-[(1*R*,2*R*)-2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1*H*-1,2,4-triazol-1-yl)propyl]quinazolin-4(3*H*)-one


albaconazole

7-chloro-3-[(1*R*,2*R*)-2-(2,4-difluorophényl)-2-hydroxy-1-méthyl-3-(1*H*-1,2,4-triazol-1-yl)propyl]quinazolin-4(3*H*)-one

albaconazol

7-cloro-3-[(1*R*,2*R*)-2-(2,4-difluorofenil)-2-hidroxi-1-metil-3-(1*H*-1,2,4-triazol-1-il)propil]quinazolin-4(3*H*)-ona

$C_{20}H_{16}ClF_2N_5O_2$



alvimopanum

alvimopan

[[[(2*S*)-2-[[[(3*R*,4*R*)-4-(3-hydroxyphenyl)-3,4-dimethylpiperidin-1-yl]methyl]-3-phenylpropanoyl]amino]acetic acid


alvimopan

acide [[[(2*S*)-2-[[[(3*R*,4*R*)-4-(3-hydroxyphényl)-3,4-diméthylpipéridin-1-yl]méthyl]-3-phénylpropanoyl]amino]acétique

alvimopán

ácido [[[(2*S*)-3-fenil-2-[[[(3*R*,4*R*)-4-(3-hidroxifenil)-3,4-dimetilpiperidin-1-il]metil]propanoil]amino]acético

$C_{28}H_{32}N_2O_4$



apaziquonum


apaziquone

5-(aziridin-1-yl)-3-(hydroxymethyl)-2-[(1*E*)-3-hydroxyprop-1-enyl]-1-methyl-1*H*-indole-4,7-dione

apaziquone

5-(aziridin-1-yl)-3-(hydroxyméthyl)-2-[(1*E*)-3-hydroxyprop-1-ényl]-1-méthyl-1*H*-indole-4,7-dione

apazicuona

5-(aziridin-1-il)-3-(hidroximetil)-2-[(1*E*)-3-hidroxiprop-1-enil]-1-metil-1*H*-indol-4,7-diona $C_{15}H_{16}N_2O_4$ **apolizumabum**

apolizumab

immunoglobulin G1, anti-(human histocompatibility antigen HLA-DR) (human-mouse monoclonal Hu1d10 γ 1-chain), disulfide with human-mouse monoclonal Hu1d10 light chain, dimer

apolizumab

immunoglobuline G1, anti-(antigène d'histocompatibilité HLA-DR humain) (chaîne γ 1 de l'anticorps monoclonal de souris Hu1d10 humanisé), dimère du disulfure avec la chaîne légère de l'anticorps monoclonal de souris Hu1d10 humanisé

apolizumab

inmunoglobulina G1, anti-(antígeno de histocompatibilidad HLA-DR humano) (cadena γ 1 del anticuerpo monoclonal humanizado de ratón Hu1d10), dímero del disulfuro con la cadena ligera del anticuerpo monoclonal humanizado de ratón Hu1d10**asenapinum**

asenapine



(3a*RS*,12b*RS*)-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1*H*-dibenzo[2,3:6,7]oxepino[4,5-*c*]pyrrole

asénapine

(3a*RS*,12b*RS*)-5-chloro-2-méthyl-2,3,3a,12b-tétrahydro-1*H*-dibenzo[2,3:6,7]oxépino[4,5-*c*]pyrrole

asenapina

(3a*RS*,12b*RS*)-5-cloro-2-metil-2,3,3a,12b-tetrahidro-1*H*-dibenzo[2,3:6,7]oxepino[4,5-*c*]pirrol



and enantiomer
et énantiomère
y enantiómero

axomadolum
axomadolum


(1*RS*,3*RS*,6*RS*)-6-[(dimethylamino)méthyl]-
1-(3-méthoxyphényl)cyclohexane-1,3-diol

axomadolum

(1*RS*,3*RS*,6*RS*)-6-[(diméthylamino)méthyl]-
1-(3-méthoxyphényl)cyclohexane-1,3-diol

axomadolum

(1*RS*,3*RS*,6*RS*)-6-[(dimetilamino)metil]-
1-(3-metoxifenil)ciclohexano-1,3-diol



and enantiomer
et énantiomère
y enantiómero

bifeprunoxum
bifeprunox



7-[4-(biphenyl-3-ylmethyl)piperazin-1-yl]benzoxazol-2(3*H*)-one

biféprunox

7-[4-(biphényl-3-ylméthyl)pipérazin-1-yl]benzoxazol-2(3*H*)-one

bifeprunox

7-[4-(bifenil-3-ilmetil)piperazin-1-il]benzoxazol-2(3*H*)-ona



canertinibum


canertinib

N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[3-(morpholin-4-yl)propoxy]quinazolin-6-yl]prop-2-enamide

canertinib

N-[4-[(3-chloro-4-fluorophényl)amino]-7-[3-(morpholin-4-yl)propoxy]quinazolin-6-yl]prop-2-énamide

canertinib

N-[4-[(3-cloro-4-fluorofenil)amino]-7-[3-(morfolin-4-il)propoxi]quinazolin-6-il]prop-2-enamida $C_{24}H_{25}ClFN_5O_3$ **cefovecinum**


cefovecin

(6*R*,7*R*)-7-[[[(2*Z*)-(2-aminothiazol-4-yl)(methoxyimino)acetyl]amino]-8-oxo-3-[(2*S*)-tetrahydrofuran-2-yl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid

céfovécine

acide (6*R*,7*R*)-7-[[[(2*Z*)-(2-aminothiazol-4-yl)(méthoxyimino)acétyl]amino]-8-oxo-3-[(2*S*)-tétrahydrofuran-2-yl]-5-thia-1-azabicyclo[4.2.0]oct-2-ène-2-carboxylique

cefovecina

ácido (6*R*,7*R*)-7-[[[(2*Z*)-(2-aminotiazol-4-il)(metoxiimino)acetil]amino]-8-oxo-3-[(2*S*)-tetrahydrofuran-2-il]-5-tia-1-azabicyclo[4.2.0]oct-2-eno-2-carboxílico $C_{17}H_{19}N_5O_6S_2$ 

cethromycinum

cethromycin


(3a*S*,4*R*,7*R*,9*R*,10*R*,11*R*,13*R*,15*R*,15a*R*)-4-ethyl-3a,7,9,11,13,15-hexamethyl-11-[[[3-(quinolin-3-yl)prop-2-enyl]oxy]-10-[[[3,4,6-trideoxy-3-(dimethylamino)-β-*D*-xylo-hexopyranosyl]oxy]octahydro-2*H*-oxacyclotetradecino[4,3-*d*]oxazole-2,6,8,14(1*H*,7*H*,9*H*)-tetrone

céthromycine

(3a*S*,4*R*,7*R*,9*R*,10*R*,11*R*,13*R*,15*R*,15a*R*)-4-éthyl-3a,7,9,11,13,15-hexaméthyl-11-[[[3-(quinoléin-3-yl)prop-2-ényl]oxy]-10-[[[3,4,6-tridésoxy-3-(diméthylamino)-β-*D*-xylo-hexopyranosyl]oxy]octahydro-2*H*-oxacyclotétradécino[4,3-*d*]oxazole-2,6,8,14(1*H*,7*H*,9*H*)-tétrone

cetromicina

(3a*S*,4*R*,7*R*,9*R*,10*R*,11*R*,13*R*,15*R*,15a*R*)-4-etil-3a,7,9,11,13,15-hexametil-11-[[[3-(quinolein-3-il)prop-2-enil]oxi]-10-[[[3,4,6-tridesoxi-3-(dimetilamino)-β-*D*-xilo-hexopiranosil]oxi]octahidro-2*H*-oxaciclótetradecino[4,3-*d*]oxazol-2,6,8,14(1*H*,7*H*,9*H*)-tetrona

 $C_{42}H_{59}N_3O_{10}$
**dabigatranum etexilatatum**

dabigatran etexilate


ethyl 3-[[[2-[[[4-[[[(hexyloxy)carbonyl]amino]iminomethyl]phenyl]amino]methyl]-1-methyl-1*H*-benzimidazol-5-yl]carbonyl](pyridin-2-yl)amino]propanoate

dabigatran étexilate


3-[[[2-[[[4-[[[(hexyloxy)carbonyl]amino]iminométhyl]phényl]amino]méthyl]-1-méthyl-1*H*-benzimidazol-5-yl]carbonyl](pyridin-2-yl)amino]propanoate d'éthyle

dabigatrán etexilato

3-[[[2-[[[4-[[[(hexiloxi)carbónil]amino]iminometil]fenil]amino]metil]-1-metil-1*H*-bencimidazol-5-il]carbónil](piridin-2-il)amino]propanoato de etilo

 $C_{34}H_{41}N_7O_5$


ecromeximabum ecromeximab	immunoglobulin G1, anti-(GD3 ganglioside) (human-mouse monoclonal KM871 γ 1-chain), disulfide with human-mouse monoclonal KM871 κ -chain, dimer
écromeximab	immunoglobuline G1, anti-(ganglioside GD3) (chaîne γ 1 de l'anticorps monoclonal chimérique homme-souris KM871), dimère du disulfure avec la chaîne κ de l'anticorps monoclonal chimérique homme-souris KM871
ecromeximab	inmunoglobulina G1, anti-(gangliósido GD3) (cadena γ 1 del anticuerpo monoclonal quimérico hombre-atón KM871), dímero del disulfuro con la cadena κ del anticuerpo monoclonal quimérico hombre-ratón KM871
eculizumabum eculizumab	immunoglobulin, anti-(human complement C5 α -chain) (human-mouse monoclonal 5G1.1 heavy chain), disulfide with human-mouse monoclonal 5G1.1 light chain, dimer
éculizumab	immunoglobuline, anti-(chaîne α du complément C5 humain) (chaîne lourde de l'anticorps monoclonal de souris 5G1.1 humanisé), dimère du disulfure avec la chaîne légère de l'anticorps monoclonal de souris 5G1.1 humanisé
eculizumab	inmunoglobulina, anti-(cadena α del complemento C5 humano) (cadena pesada del anticuerpo monoclonal humanizado de ratón 5G1.1), dímero del disulfuro con la cadena ligera del anticuerpo monoclonal humanizado de ratón 5G1.1
elzasonanum elzasonan	(2Z)-4-(3,4-dichlorophenyl)-2-[2-(4-methylpiperazin-1-yl)benzylidene]thiomorpholin-3-one
elzasonan	(2Z)-4-(3,4-dichlorophényl)-2-[2-(4-méthylpipérazin-1-yl)benzylidène]thiomorpholin-3-one
elzasonán	(2Z)-4-(3,4-diclorofenil)-2-[2-(4-metilpiperazin-1-il)benzilideno]tiomorfolin-3-ona

$$C_{22}H_{23}Cl_2N_3OS$$


enecadinum

enecadin


4-(4-fluorophenyl)-2-methyl-6-[[5-(piperidin-1-yl)pentyl]oxy]pyrimidine

énécadine

4-(4-fluorophényl)-2-méthyl-6-[[5-(pipéridin-1-yl)pentyl]oxy]pyrimidine

enecadina

4-(4-fluorofenil)-2-metil-6-[[5-(piperidin-1-il)pentil]oxi]pirimidina

 $C_{21}H_{28}FN_3O$ **ertiprotafibum**


ertiprotafib

(2*R*)-2-[4-(9-bromo-2,3-dimethylnaphtho[2,3-*b*]thiophen-4-yl)-2,6-dimethylphenoxy]-3-phenylpropanoic acid

ertiprotafib

acide (2*R*)-2-[4-(9-bromo-2,3-diméthylnaphto[2,3-*b*]thiophén-4-yl)-2,6-diméthylphénoxy]-3-phénylpropanoïque

ertiprotafib

ácido (2*R*)-2-[4-(9-bromo-2,3-dimetilnafto[2,3-*b*]tiofen-4-il)-2,6-dimetilfenoxi]-3-fenilpropanoico $C_{31}H_{27}BrO_3S$ **eszopiclonum**


eszopiclone

(5*S*)-6-(5-chloropyridin-2-yl)-7-oxo-6,7-dihydro-5*H*-pyrrolo[3,4-*b*]pyrazin-5-yl-4-methylpiperazine-1-carboxylate

eszopiclone

4-méthylpipérazine-1-carboxylate de (5*S*)-6-(5-chloropyridin-2-yl)-7-oxo-6,7-dihydro-5*H*-pyrrolo[3,4-*b*]pyrazin-5-yle

eszopiclona

4-metilpiperazina-1-carboxilato de (5*S*)-6-(5-cloropiridin-2-il)-7-oxo-6,7-dihidro-5*H*-pirrolo[3,4-*b*]pirazin-5-ilo $C_{17}H_{17}ClN_6O_3$ 

fandosentanum


fandosentan

4-(7-ethyl-1,3-benzodioxol-5-yl)-2-[2-(trifluoromethyl)phenyl]-
2*H*-1,2-benzothiazine-3-carboxylic acid 1,1-dioxide

fandosentan

1,1-dioxyde de l'acide 4-(7-éthyl-1,3-benzodioxol-5-yl)-
2-[2-(trifluorométhyl)phényl]-2*H*-1,2-benzothiazine-3-carboxylique

fandosentan

1,1-dióxido del ácido 4-(7-etil-1,3-benzodioxol-5-il)-2-[2-(trifluorometil)fenil]-
2*H*-1,2-benzotiazina-3-carboxílico $C_{25}H_{18}F_3NO_6S$ **fontolizumabum**

fontolizumab

immunoglobulin G1, anti-(human interferon γ) (human-mouse monoclonal
HuZAF γ 1-chain), disulfide with human-mouse monoclonal HuZAF light
chain, dimer

fontolizumab

immunoglobuline G1, anti-(interféron γ humain) (chaîne γ 1 de l'anticorps
monoclonal de souris HuZAF humanisé), dimère du disulfure avec la
chaîne légère de l'anticorps monoclonal de souris HuZAF humanisé

fontolizumab

inmunoglobulina G1, anti-(interferón γ humano) (cadena γ 1 del anticuerpo
monoclonal humanizado de ratón HuZAF), dímero del disulfuro con la
cadena ligera del anticuerpo monoclonal humanizado de ratón HuZAF**garenoxacinum**


garenoxacin

1-cyclopropyl-8-(difluoromethoxy)-7-[(1*R*)-1-methyl-2,3-dihydro-
1*H*-isoindol-5-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid

garénoxacine

acide 1-cyclopropyl-8-(difluorométhoxy)-7-[(1*R*)-1-méthyl-2,3-dihydro-
1*H*-isoindol-5-yl]-4-oxo-1,4-dihydroquinoléine-3-carboxylique

garenoxacina

ácido 1-ciclopropil-8-(difluorometoxi)-7-[(1*R*)-1-metil-2,3-dihidro-
1*H*-isoindol-5-il]-4-oxo-1,4-dihidroquinolina-3-carboxílico $C_{23}H_{20}F_2N_2O_4$ 

inecalcitolum


inecalcitol

(7*E*)-19-nor-9,10-seco-14β-cholesta-5,7-dien-23-yne-1α,3β,25-triol

inécalcitol

(7*E*)-19-nor-9,10-séco-14β-cholesta-5,7-dién-23-yne-1α,3β,25-triol

inecalcitol

(7*E*)-19-nor-9,10-seco-14β-colesta-5,7-dien-23-ino-1α,3β,25-triol $C_{26}H_{40}O_3$ **iroxanadinum**


iroxanadine

(-)-5-(piperidin-1-ylmethyl)-3-(pyridin-3-yl)-5,6-dihydro-2*H*-1,2,4-oxadiazine

iroxanadine

(-)-5-(pipéridin-1-ylméthyl)-3-(pyridin-3-yl)-5,6-dihydro-2*H*-1,2,4-oxadiazine

iroxanadina

(-)-5-(piperidin-1-ilmetil)-3-(piridin-3-il)-5,6-dihidro-2*H*-1,2,4-oxadiazina $C_{14}H_{20}N_4O$ 

or enantiomer
ou énantiomère
o enantiómero

lidorestatum


lidorestat




[3-[(4,5,7-trifluorobenzothiazol-2-yl)methyl]-1*H*-indol-1-yl]acetic acid

lidorestat

acide [3-[(4,5,7-trifluorobenzothiazol-2-yl)méthyl]-1*H*-indol-1-yl]acétique

lidorestat



ácido [3-[(4,5,7-trifluorobenzotiazol-2-il)metil]-1*H*-indol-1-il]acético $C_{18}H_{11}F_3N_2O_2S$ 

liraglutidumliraglutide *N*²⁶-(hexadecanoyl-γ-glutamyle)-[34-arginine]GLP-1-(7-37)-peptideliraglutide *N*²⁶-(hexadécanoyl-γ-glutamyle)-[34-arginine]GLP-1-(7-37)-peptideliraglutida *N*²⁶-(hexadecanoil-γ-glutamilo)-[34-arginina]GLP-1-(7-37)-péptido**lubiprostonum**lubiprostone (-)-7-[(2*R*,4*aR*,5*R*,7*aR*)-2-(1,1-difluoropentyl)-2-hydroxy-6-oxooctahydrocyclopenta[*b*]pyran-5-yl]heptanoic acidlubiprostone (-)-acide 7-[(2*R*,4*aR*,5*R*,7*aR*)-2-(1,1-difluoropentyl)-2-hydroxy-6-oxooctahydrocyclopenta[*b*]pyran-5-yl]heptanoïquelubiprostone (-)-ácido 7-[(2*R*,4*aR*,5*R*,7*aR*)-2-(1,1-difluoropentil)-2-hidroxi-6-oxooctahidrociclopenta[*b*]piran-5-il]heptanoico**lumiracoxibum**

lumiracoxib [2-[(2-chloro-6-fluorophenyl)amino]-5-methylphenyl]acetic acid

lumiracoxib acide [2-[(2-chloro-6-fluorophényl)amino]-5-méthylphényl]acétique

lumiracoxib ácido [2-[(2-cloro-6-fluorofenil)amino]-5-metilfenil]acético

**merimepodibum**


merimepodib

(3*S*)-tetrahydrofuran-3-yl [3-[[[3-methoxy-4-(oxazol-5-yl)phenyl]carbamoyl]amino]benzyl]carbamate

mérimépodib

[3-[[[3-méthoxy-4-(oxazol-5-yl)phényl]carbamoyl]amino]benzyl]carbamate de (3*S*)-tétrahydrofuran-3-yle

merimepodib

[3-[[[3-metoxi-4-(oxazol-5-il)fenil]carbamoil]amino]bencil]carbamato de (3*S*)-tetrahidrofuran-3-ilo**mozavaptanum**



mozavaptan

N-[4-[[[(5*RS*)-5-(dimethylamino)-2,3,4,5-tetrahydro-1*H*-1-benzazepin-1-yl]carbonyl]phenyl]-2-methylbenzamide

mozavaptan

N-[4-[[[(5*RS*)-5-(diméthylamino)-2,3,4,5-tétrahydro-1*H*-1-benzazépin-1-yl]carbonyl]phényl]-2-méthylbenzamide

mozavaptán


N-[4-[[[(5*RS*)-5-(dimetilamino)-2,3,4,5-tetrahydro-1*H*-1-benzazepin-1-il]carbonil]fenil]-2-metilbenzamidaand enantiomer
et énantiomère
y enantiómero

nalfurafinum
nalfurafine*(E)*-*N*-[17-(cyclopropylmethyl)-4,5 α -epoxy-3,14-dihydroxymorphinan-6 β -yl]-3-(furan-3-yl)-*N*-methylprop-2-enamide

nalfurafine

(E)-*N*-[17-(cyclopropylméthyl)-4,5 α -époxy-3,14-dihydroxymorphinan-6 β -yl]-3-(furan-3-yl)-*N*-méthylprop-2-énamide

nalfurafina

(E)-*N*-[17-(ciclopropilmetil)-4,5 α -epoxi-3,14-dihidroximorfinan-6 β -il]-3-(furan-3-il)-*N*-metilprop-2-enamida $C_{28}H_{32}N_2O_5$ **naminidilum**


naminidil

N-cyano-*N'*-(4-cyanophenyl)-*N''*-[(1*R*)-1,2,2-trimethylpropyl]guanidine

naminidil

N-cyano-*N'*-(4-cyanophényl)-*N''*-[(1*R*)-1,2,2-triméthylpropyl]guanidine

naminidil

N-ciano-*N'*-(4-cianofenil)-*N''*-[(1*R*)-1,2,2-trimetilpropil]guanidina $C_{15}H_{19}N_5$ **nemifitidum**

nemifitide



4-fluoro-L-phenylalanyl-*trans*-4-hydroxy-L-prolyl-L-arginylglycyl-L-tryptophanamide

némifitide

(4-fluoro-L-phénylalanil)-(trans-4-hydroxy-L-prolyl)-L-arginyl-glycyl-L-tryptophanamide

nemifitida

(4-fluoro-L-fenilalanil)-(trans-4-hidroxi-L-prolil)-L-arginilglicil-L-triptofanamida



nortopixantrone
nortopixantrone



2-[2-[(2-hydroxyethyl)amino]ethyl]-
5-[[2-(methylamino)ethyl]amino]indazolo[4,3-*gh*]isoquinolin-6(2*H*)-one

nortopixantrone

2-[2-[(2-hydroxyéthyl)amino]éthyl]-
5-[[2-(méthylamino)éthyl]amino]indazolo[4,3-*gh*]isoquinoléin-6(2*H*)-one

nortopixantrona

2-[2-[(2-hidroxietil)amino]etil]-
5-[[2-(metilamino)etil]amino]indazolo[4,3-*gh*]isoquinolin-6(2*H*)-ona



oblimersenum

oblimersen


P-thiothymidyl-(3'→5')-2'-deoxy-*P*-thiocytidyl-(3'→5')-*P*-thiothymidyl-(3'→5')-2'-deoxy-*P*-thiocytidyl-(3'→5')-2'-deoxy-*P*-thiocytidyl-(3'→5')-2'-deoxy-*P*-thioadenyl-(3'→5')-2'-deoxy-*P*-thioguanyl-(3'→5')-2'-deoxy-*P*-thiocytidyl-(3'→5')-2'-deoxy-*P*-thioguanyl-(3'→5')-*P*-thiothymidyl-(3'→5')-2'-deoxy-*P*-thioguanyl-(3'→5')-2'-deoxy-*P*-thiocytidyl-(3'→5')-2'-deoxy-*P*-thioguanyl-(3'→5')-2'-deoxy-*P*-thiocytidyl-(3'→5')-2'-deoxy-*P*-thioadenyl-(3'→5')-thymidine

oblimersen

P-thiothymidyl-(3'→5')-2'-désoxy-*P*-thiocytidyl-(3'→5')-*P*-thiothymidyl-(3'→5')-2'-désoxy-*P*-thiocytidyl-(3'→5')-2'-désoxy-*P*-thiocytidyl-(3'→5')-2'-désoxy-*P*-thioadényl-(3'→5')-2'-désoxy-*P*-thioguanyl-(3'→5')-2'-désoxy-*P*-thiocytidyl-(3'→5')-2'-désoxy-*P*-thioguanyl-(3'→5')-*P*-thiothymidyl-(3'→5')-2'-désoxy-*P*-thioguanyl-(3'→5')-2'-désoxy-*P*-thiocytidyl-(3'→5')-2'-désoxy-*P*-thioguanyl-(3'→5')-2'-désoxy-*P*-thiocytidyl-(3'→5')-2'-désoxy-*P*-thioadényl-(3'→5')-thymidine

oblimerseno

P-tiotimidilil-(3'→5')-2'-desoxi-*P*-tiocitidilil-(3'→5')-*P*-tiotimidilil-(3'→5')-2'-desoxi-*P*-tiocitidilil-(3'→5')-2'-desoxi-*P*-tiocitidilil-(3'→5')-2'-desoxi-*P*-tiocitidilil-(3'→5')-2'-desoxi-*P*-tioguanilil-(3'→5')-2'-desoxi-*P*-tiocitidilil-(3'→5')-2'-desoxi-*P*-tioguanilil-(3'→5')-*P*-tiotimidilil-(3'→5')-2'-desoxi-*P*-tioguanilil-(3'→5')-2'-desoxi-*P*-tiocitidilil-(3'→5')-2'-desoxi-*P*-tioguanilil-(3'→5')-2'-desoxi-*P*-tiocitidilil-(3'→5')-2'-desoxi-*P*-tiocitidilil-(3'→5')-2'-desoxi-*P*-tiocitidilil-(3'→5')-timidina

**ortataxelum**

ortataxel


(3*aS*,4*R*,5*E*,7*R*,8*aS*,9*S*,10*aR*,12*aS*,12*bR*,13*S*,13*aS*)-7,12a-bis(acetyloxy)-13-(benzoyloxy)-9-hydroxy-5,8a,14,14-tetramethyl-2,8-dioxo-3a,4,7,8,8a,9,10,10a,12,12a,12b,13-dodecahydro-6,13a-methano-13a*H*-oxeto[2'',3'':5',6']benzo[1',2':4,5]cyclodeca[1,2-*d*]-1,3-dioxol-4-yl (2*R*,3*S*)-3-[[[(1,1-dimethylethoxy)carbonyl]amino]-2-hydroxy-5-methylhexanoate

ortataxel

(2*R*,3*S*)-3-[[[(1,1-diméthyléthoxy)carbonyl]amino]-2-hydroxy-5-méthylhexanoate de (3*aS*,4*R*,5*E*,7*R*,8*aS*,9*S*,10*aR*,12*aS*,12*bR*,13*S*,13*aS*)-7,12a-bis(acétyloxy)-13-(benzoyloxy)-9-hydroxy-5,8a,14,14-tétraméthyl-2,8-dioxo-3a,4,7,8,8a,9,10,10a,12,12a,12b,13-dodécahydro-6,13a-méthano-13a*H*-oxéto[2'',3'':5',6']benzo[1',2':4,5]cyclodéca[1,2-*d*]-1,3-dioxol-4-yle

ortataxel

(2*R*,3*S*)-3-[[[(1,1-dimetiletoxi)carbonil]amino]-2-hidroxi-5-metilhexanoato de (3*aS*,4*R*,5*E*,7*R*,8*aS*,9*S*,10*aR*,12*aS*,12*bR*,13*S*,13*aS*)-7,12a-bis(acetiloxi)-13-(benzoiloxi)-9-hidroxi-5,8a,14,14-tetrametil-2,8-dioxo-3a,4,7,8,8a,9,10,10a,12,12a,12b,13-dodecahidro-6,13a-metano-13a*H*-oxeto[2'',3'':5',6']benzo[1',2':4,5]ciclodeca[1,2-*d*]-1,3-dioxol-4-ilo

**osemozotanum**


osemozotan

3-(1,3-benzodioxol-5-yloxy)-*N*-[[(2*S*)-2,3-dihydro-1,4-benzodioxin-2-yl]methyl]propan-1-amine

osémozotan

3-(1,3-benzodioxol-5-yloxy)-*N*-[[(2*S*)-2,3-dihydro-1,4-benzodioxin-2-yl]méthyl]propan-1-amine

osemozotán

3-(1,3-benzodioxol-5-iloxi)-*N*-[[(2*S*)-2,3-dihidro-1,4-benzodioxin-2-il]metil]propan-1-amina**pascolizumabum**

pascolizumab

immunoglobulin G1, anti-(human interleukin 4) (human-mouse monoclonal SB-240683 γ 1-chain), disulfide with human-mouse monoclonal SB-240683 κ -chain, dimer

pascolizumab

immunoglobuline G1, anti-(interleukine 4 humaine) (chaîne γ 1 de l'anticorps monoclonal de souris SB-240683 humanisé), dimère du disulfure avec la chaîne κ de l'anticorps monoclonal de souris SB-240683 humanisé

pascolizumab

inmunoglobulina G1, anti-(interleukina 4 humana) (cadena γ 1 del anticuerpo monoclonal humanizado de ratón SB-240683), dímero del disulfuro con la cadena κ del anticuerpo monoclonal humanizado de ratón SB-240683

pegaptanibum
pegaptanib


5'-ester of (2'-deoxy-2'-fluoro)C-Gm-Gm-A-A-(2'-deoxy-2'-fluoro)U-(2'-deoxy-2'-fluoro)C-Am-Gm-(2'-deoxy-2'-fluoro)U-Gm-Am-Am-(2'-deoxy-2'-fluoro)U-Gm-(2'-deoxy-2'-fluoro)C-(2'-deoxy-2'-fluoro)U-(2'-deoxy-2'-fluoro)U-Am-(2'-deoxy-2'-fluoro)U-Am-(2'-deoxy-2'-fluoro)C-Am-(2'-deoxy-2'-fluoro)U-(2'-deoxy-2'-fluoro)C-(2'-deoxy-2'-fluoro)C-Gm-(3'→3')-dT with α, α' -[[[(1S)-1-[[5-(phosphonoxy)pentyl]carbamoyl]pentane-1,5-diyl]bis(iminocarbonyl)]bis[ω -methoxypoly(oxyethane-1,2-diyl)]]

pégaptanib


(2'-désoxy-2'-fluoro)C-Gm-Gm-A-A-(2'-désoxy-2'-fluoro)U-(2'-désoxy-2'-fluoro)C-Am-Gm-(2'-désoxy-2'-fluoro)U-Gm-Am-Am-(2'-désoxy-2'-fluoro)U-Gm-(2'-désoxy-2'-fluoro)C-(2'-désoxy-2'-fluoro)U-(2'-désoxy-2'-fluoro)U-Am-(2'-désoxy-2'-fluoro)U-Am-(2'-désoxy-2'-fluoro)C-Am-(2'-désoxy-2'-fluoro)U-(2'-désoxy-2'-fluoro)C-(2'-désoxy-2'-fluoro)C-Gm-(3'→3')-dT 5'-estérifié par α, α' -[[[(1S)-1-[[5-(phosphonoxy)pentyl]carbamoyl]pentane-1,5-diyl]bis(iminocarbonyl)]bis[ω -méthoxypoly(oxyéthane-1,2-diyl)]]

pegaptanib

(2'-desoxi-2'-fluoro)C-Gm-Gm-A-A-(2'-desoxi-2'-fluoro)U-(2'-desoxi-2'-fluoro)C-Am-Gm-(2'-desoxi-2'-fluoro)U-Gm-Am-Am-(2'-desoxi-2'-fluoro)U-Gm-(2'-desoxi-2'-fluoro)C-(2'-desoxi-2'-fluoro)U-(2'-desoxi-2'-fluoro)U-Am-(2'-desoxi-2'-fluoro)U-Am-(2'-desoxi-2'-fluoro)C-Am-(2'-desoxi-2'-fluoro)U-(2'-desoxi-2'-fluoro)C-(2'-desoxi-2'-fluoro)C-Gm-(3'→3')-dT 5'-esterificado con α, α' -[[[(1S)-1-[[5-(fosfonooxi)pentil]carbamoi]pentano-1,5-diil]bis(iminocarbonil)]bis[ω -metoxipoli(oxiétano-1,2-diilo)]]



$$x + y = n$$

**pegsunerceptum**
pegsunercept

pegylated L-methionyl-1-105-human tumor necrosis factor receptor p55

pegsunercept

L-méthionyl-1-105-récepteur p55 du facteur de nécrose tumorale humain, pegylé

pegsunercept

L-metionil-1-105-receptor p55 del factor de necrosis tumoral humano, pegilado

$C_{502}H_{758}N_{154}O_{165}S_{16}$ (protein portion)

M

DSVCPQGKYI HPQNNSICCT KCHKGTLYYN DCPGPGQDTD
 CRECESGSFT ASENHLRHCL SCSKCRKEMG QVEISSCTVD
 RDTVCGCRKN QYRHYWSENLFQCFN

perflubrodecum

perflubrodec


1-bromohenicosafuorodecane

perflubrodec

1-bromohénicosafuorodécane

perflubrodec

1-bromohenicosafuorodecano

 $C_{10}BrF_{21}$
**picoplatinum**

picoplatin


(SP-4-3)-amminedichloro(2-methylpyridine)platinum

picoplatine

(SP-4-3)-amminedichloro(2-méthylpyridine)platine

picoplatino

(SP-4-3)-aminodicloro(2-metilpiridina)platino

 $C_6H_{10}Cl_2N_2Pt$


plevitrexedum


plevitrexed

(2*S*)-2-[[4-[[[(2,7-dimethyl-4-oxo-1,4-dihydroquinazolin-6-yl)methyl](prop-2-ynyl)amino]-2-fluorobenzoyl]amino]-4-(1*H*-tetrazol-5-yl)butanoic acid

plévitrexed

acide (2*S*)-2-[[4-[[[(2,7-diméthyl-4-oxo-1,4-dihydroquinazolin-6-yl)méthyl]](prop-2-ynyl)amino]-2-fluorobenzoyl]amino]-4-(1*H*-tétrazol-5-yl)butanoïque

plevitrexed

ácido (2*S*)-2-[[4-[[[(2,7-dimetil-4-oxo-1,4-dihidroquinazolin-6-il)metil]](prop-2-inil)amino]-2-fluorobenzoi]]amino]-4-(1*H*-tetrazol-5-il)butanoico $C_{26}H_{25}FN_8O_4$ **pumosetragum**


pumosetrag

N-[(3*R*)-1-azabicyclo[2.2.2]oct-3-yl]-7-oxo-4,7-dihydrothieno[3,2-*b*]pyridine-6-carboxamide

pumosétrag

N-[(3*R*)-1-azabicyclo[2.2.2]oct-3-yl]-7-oxo-4,7-dihydrothiéno[3,2-*b*]pyridine-6-carboxamide

pumosetrag

N-[(3*R*)-1-azabicyclo[2.2.2]oct-3-il]-7-oxo-4,7-dihidrotieno[3,2-*b*]piridina-6-carboxamida $C_{15}H_{17}N_3O_2S$ **siplizumabum**

siplizumab

immunoglobulin G1, anti-(human CD2 (antigen)) (human-rat monoclonal MEDI-507 γ 1-chain), disulfide with human-rat monoclonal MEDI-507 light chain, dimer

siplizumab

immunoglobuline G1, anti-(antigène humain CD2) (chaîne γ 1 de l'anticorps monoclonal de rat MEDI-507 humanisé), dimère du disulfure avec la chaîne légère de l'anticorps monoclonal de rat MEDI-507 humanisé

siplizumab

inmunoglobulina G1, anti-(antígeno humano CD2) (cadena γ 1 del anticuerpo monoclonal de rata humanizado MEDI-507), dímero del disulfuro con la cadena ligera del anticuerpo monoclonal de rata humanizado MEDI-507

soraprazanum


soraprazan

(7*R*,8*R*,9*R*)-7-(2-methoxyethoxy)-2,3-dimethyl-9-phenyl-7,8,9,10-tetrahydroimidazo[1,2-*h*][1,7]naphthyridin-8-ol

soraprazan

(7*R*,8*R*,9*R*)-7-(2-méthoxyéthoxy)-2,3-diméthyl-9-phényl-7,8,9,10-tétrahydroimidazo[1,2-*h*][1,7]naphtyridin-8-ol

soraprazán

(7*R*,8*R*,9*R*)-9-fenil-2,3-dimetil-7-(2-metoxietoxi)-7,8,9,10-tetrahidroimidazo[1,2-*h*][1,7]naftiridin-8-ol $C_{21}H_{25}N_3O_3$ **tapentadolum**


tapentadol

3-[(1*R*,2*R*)-3-(dimethylamino)-1-ethyl-2-methylpropyl]phenol

tapentadol

3-[(1*R*,2*R*)-3-(diméthylamino)-1-éthyl-2-méthylpropyl]phénol

tapentadol

3-[(1*R*,2*R*)-3-(dimetilamino)-1-etil-2-metilpropil]fenol $C_{14}H_{23}NO$ **tecadenosonum**

tecadenoson



9-β-D-ribofuranosyl-*N*-[(3*R*)-tetrahydrofuran-3-yl]-9*H*-purin-6-amine

técadénoson

9-β-D-ribofuranosyl-*N*-[(3*R*)-tétrahydrofuran-3-yl]-9*H*-purin-6-amine

tecadenosón

9-β-D-ribofuranosil-*N*-[(3*R*)-tetrahidrofuran-3-il]-9*H*-purin-6-amina

**tecalcetum**



tecalcet

3-(2-chlorophenyl)-*N*-[(1*R*)-1-(3-methoxyphenyl)ethyl]propan-1-amine

técalcet

3-(2-chlorophényl)-*N*-[(1*R*)-1-(3-méthoxyphényl)éthyl]propan-1-amine

tecalcet

3-(2-clorofenil)-*N*-[(1*R*)-1-(3-metoxifenil)etil]propan-1-amina**teneliximabum**

teneliximab

immunoglobulin G1, anti-(human CD40 (antigen)) (human-mouse monoclonal chi220 γ 1-chain), disulfide with human-mouse monoclonal chi220 light chain, dimer

téneliximab

immunoglobuline G1, anti-(antigène CD40 humain) (chaîne γ 1 de l'anticorps monoclonal chimérique homme souris chi220), dimère du disulfure avec la chaîne légère de l'anticorps monoclonal chimérique homme souris chi220

teneliximab

inmunoglobulina G1, anti-(antígeno CD40 humano) (cadena γ 1 del anticuerpo monoclonal quimérico hombre ratón chi220), dímero del disulfuro con la cadena ligera del anticuerpo monoclonal quimérico hombre ratón chi220

topixantronum


topixantrone

5-[[2-(dimethylamino)ethyl]amino]-
2-[2-[(2-hydroxyethyl)amino]ethyl]indazolo[4,3-*gh*]isoquinolin-6(2*H*)-one

topixantrone

5-[[2-(diméthylamino)éthyl]amino]-
2-[2-[(2-hydroxyéthyl)amino]éthyl]indazolo[4,3-*gh*]isoquinoléin-6(2*H*)-one

topixantrona

5-[[2-(dimetilamino)etil]amino]-
2-[2-[(2-hidroxietil)amino]etil]indazolo[4,3-*gh*]isoquinolin-6(2*H*)-ona $C_{21}H_{26}N_6O_2$ **toralizumabum**

toralizumab

immunoglobulin G1, anti-(human CD40 ligand) (human-mouse monoclonal IDEC-131 γ 1-chain), disulfide with human-mouse monoclonal IDEC-131 κ -chain, dimer

toralizumab

immunoglobuline G1, anti-(ligand CD40 humain) (chaîne γ 1 de l'anticorps monoclonal de souris IDEC-131 humanisé), dimère du disulfure avec la chaîne κ de l'anticorps monoclonal de souris IDEC-131 humanisé

toralizumab

inmunoglobulina G1, anti-(ligando CD40 humano) (cadena γ 1 del anticuerpo monoclonal humanizado de ratón IDEC-131), dímero del disulfuro con la cadena κ del anticuerpo monoclonal humanizado de ratón IDEC-131**torcetrapibum**


torcetrapib



ethyl (2*R*,4*S*)-4-[[3,5-bis(trifluoromethyl)benzyl](methoxycarbonyl)amino]-2-ethyl-6-(trifluoromethyl)-3,4-dihydroquinoline-1(2*H*)-carboxylate


torcétrapib

(2*R*,4*S*)-4-[[3,5-bis(trifluorométhyl)benzyl](méthoxycarbonyl)amino]-2-éthyl-6-(trifluorométhyl)-3,4-dihydroquinoléine-1(2*H*)-carboxylate d'éthyle

torcetrapib

(2*R*,4*S*)-4-[[3,5-bis(trifluorometil)bencil](metoxicarbonil)amino]-2-etil-6-(trifluorometil)-3,4-dihidroquinolina-1(2*H*)-carboxilato de etilo $C_{25}H_{25}F_9N_2O_4$ 

torcitabinumtorcitabine 4-amino-1-(2-deoxy-β-L-*erythro*-pentofuranosyl)pyrimidin-2(1*H*)-onetorcitabine 4-amino-1-(2-désoxy-β-L-*érythro*-pentofuranosyl)pyrimidin-2(1*H*)-onetorcitabina 4-amino-1-(2-desoxi-β-L-*eritro*-pentofuranosil)pirimidin-2(1*H*)-ona**treprostinilum**treprostinil [[[(1*R*,2*R*,3*aS*,9*aS*)-2-hydroxy-1-[(3*S*)-3-hydroxyoctyl]-2,3,3*a*,4,9,9*a*-hexahydro-1*H*-cyclopenta[*b*]naphthalen-5-yl]oxy]acetic acidtréprostinil acide [[[(1*R*,2*R*,3*aS*,9*aS*)-2-hydroxy-1-[(3*S*)-3-hydroxyoctyl]-2,3,3*a*,4,9,9*a*-hexahydro-1*H*-cyclopenta[*b*]naphthalén-5-yl]oxy]acétiquetreprostinilo ácido [[[(1*R*,2*R*,3*aS*,9*aS*)-2-hidroxi-1-[(3*S*)-3-hidroxiocetil]-2,3,3*a*,4,9,9*a*-hexahidro-1*H*-ciclopenta[*b*]naftalen-5-il]oxi]acético**triplatinum tetranitras**triplatin tetranitrate *trans*-[bis[*trans*-diamminechloroplatinium(μ-hexane-1,6-diamine)]]diammineplatinum tetranitratetétranitrate de triplatine tétranitrate de *trans*-[bis[*trans*-diamminechloroplatine(μ-hexane-1,6-diamine)]]diammineplatinetetranitrato de triplatino tetranitrato de *trans*-[bis[*trans*-diaminacloroplatino(μ-hexano-1,6-diamina)]]diaminaplato



tulathromycinum
tulathromycin

Mixture of two compounds (in equilibrium in solution):

tulathromycinum A
(2*R*,3*S*,4*R*,5*R*,8*R*,10*R*,11*R*,12*S*,13*S*,14*R*)-13-[(2,6-dideoxy-3-*C*-methyl-3-*O*-methyl-4-*C*-[(propylamino)methyl]-α-*L*-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,8,10,12,14-hexamethyl-11-[[3,4,6-trideoxy-3-(dimethylamino)-β-*D*-xylo-hexopyranosyl]oxy]-1-oxa-6-azacyclopentadecan-15-one
tulathromycinum B
(2*R*,3*R*,6*R*,8*R*,9*R*,10*S*,11*S*,12*R*)-11-[(2,6-dideoxy-3-*C*-methyl-3-*O*-methyl-4-*C*-[(propylamino)methyl]-α-*L*-ribo-hexopyranosyl)oxy]-2-[(1*R*,2*R*)-1,2-dihydroxy-1-methylbutyl]-8-hydroxy-3,6,8,10,12-pentamethyl-9-[[3,4,6-trideoxy-3-(dimethylamino)-β-*D*-xylo-hexopyranosyl]oxy]-1-oxa-4-azacyclotridecan-13-one

tulathromycine

Mélange de deux composés (en équilibre en solution):



tulathromycinum A
(2*R*,3*S*,4*R*,5*R*,8*R*,10*R*,11*R*,12*S*,13*S*,14*R*)-13-[(2,6-didésoxy-3-*C*-méthyl-3-*O*-méthyl-4-*C*-[(propylamino)méthyl]-α-*L*-ribo-hexopyranosyl)oxy]-2-éthyl-3,4,10-trihydroxy-3,5,8,10,12,14-hexaméthyl-11-[[3,4,6-tridésoxy-3-(diméthylamino)-β-*D*-xylo-hexopyranosyl]oxy]-1-oxa-6-azacyclopentadécan-15-one
tulathromycinum B
(2*R*,3*R*,6*R*,8*R*,9*R*,10*S*,11*S*,12*R*)-11-[(2,6-didésoxy-3-*C*-méthyl-3-*O*-méthyl-4-*C*-[(propylamino)méthyl]-α-*L*-ribo-hexopyranosyl)oxy]-2-[(1*R*,2*R*)-1,2-dihydroxy-1-méthylbutyl]-8-hydroxy-3,6,8,10,12-pentaméthyl-9-[[3,4,6-tridésoxy-3-(diméthylamino)-β-*D*-xylo-hexopyranosyl]oxy]-1-oxa-4-azacyclotridécan-13-one

tulatromicina

Mezcla de dos componentes (en equilibrio en solución):

tulathromycinum A
(2*R*,3*S*,4*R*,5*R*,8*R*,10*R*,11*R*,12*S*,13*S*,14*R*)-13-[(2,6-didesoxi-3-*C*-metil-3-*O*-metil-4-*C*-[(propilamino)metil]-α-*L*-ribo-hexopiranosil)oxi]-2-etil-3,4,10-trihidroxi-3,5,8,10,12,14-hexametil-11-[[3,4,6-tridesoxi-3-(dimetilamino)-β-*D*-xilo-hexopiranosil]oxi]-1-oxa-6-azaciclopentadecan-15-ona
tulathromycinum B
(2*R*,3*R*,6*R*,8*R*,9*R*,10*S*,11*S*,12*R*)-11-[(2,6-didesoxi-3-*C*-metil-3-*O*-metil-4-*C*-[(propilamino)metil]-α-*L*-ribo-hexopiranosil)oxi]-2-[(1*R*,2*R*)-1,2-dihidroxi-1-metilbutil]-8-hidroxi-3,6,8,10,12-pentametil-9-[[3,4,6-tridesoxi-3-(dimetilamino)-β-*D*-xilo-hexopiranosil]oxi]-1-oxa-4-azaciclortridecan-13-ona

$C_{41}H_{79}N_3O_{12}$ tulathromycinum A
 $C_{41}H_{79}N_3O_{12}$ tulathromycinum B



vapaliximabum
vapaliximab

immunoglobulin G2, anti-(human vascular adhesion protein VAP-1) (human-mouse monoclonal 2D10 γ 2-chain), disulfide with human-mouse monoclonal 2D10 κ -chain, dimer

vapaliximab

immunoglobuline G2, anti-(protéine d'adhésion vasculaire humaine VAP-1) (chaîne γ 2 de l'anticorps monoclonal chimérique homme-souris 2D10), dimère du disulfure avec la chaîne κ de l'anticorps monoclonal chimérique homme-souris 2D10

vapaliximab

inmunoglobulina G2, anti-(proteína de adhesión vascular humana VAP-1) (cadena γ 2 del anticuerpo monoclonal quimérico hombre-ratón 2D10), dímero del disulfuro con la cadena κ del anticuerpo monoclonal quimérico hombre-ratón 2D10

varespladibum


varespladib

[[3-(aminooxoacetyl)-1-benzyl-2-ethyl-1*H*-indol-4-yl]oxy]acetic acid

varespladib

acide [[3-(aminooxoacétyl)-1-benzyl-2-éthyl-1*H*-indol-4-yl]oxy]acétique

varespladib

ácido [[3-(aminooxoacetil)-1-bencil-2-etil-1*H*-indol-4-il]oxi]acético $C_{21}H_{20}N_2O_5$ 

**AMENDMENTS TO PREVIOUS LISTS
MODIFICATIONS APPORTÉES AUX LISTES ANTÉRIEURES
MODIFICACIONES A LAS LISTAS ANTERIORES**

Recommended International Nonproprietary Names (Rec. INN): List 46
Dénominations communes internationales recommandées (DCI Rec.): Liste 46
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 46
(WHO Drug Information, Vol. 15, No. 3-4, 2001)

- P. 208 **reglitazarum**
reglitazar
sustituyase la descripción por la siguiente:
(4*RS*)-4-[4-[2-fenil-5-metiloxazol-4-il)etoxi]bencil]isoxazolidina-3,5-diona
- P. 208 **rivoglitazonum**
rivoglitazona
sustituyase la descripción por la siguiente:
(5*RS*)-5-[4-[(1-metil-6-metoxi-1*H*-bencimidazol-2-il)metoxi]bencil]tiazolidina-2,4-diona
- P. 217 *delete/supprimer/suprimase*
tebipenemum
tebipenem
tébipénem
tebipenem
insert/insérer/insértase
tebipenemum pivoxilum
tebipenem pivoxil
tébipénem pivoxil
tebipenem pivoxilo

Recommended International Nonproprietary Names (Rec. INN): List 48
Dénominations communes internationales recommandées (DCI Rec.): Liste 48
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 48
(WHO Drug Information, Vol. 16, No. 3, 2002)

- P. 255 **metelimumabum**
metelimumab
replace the description by the following:
immunoglobulin G4, anti-(human transforming growth factor β 1)
(human monoclonal CAT-192 γ 4-chain), disulfide with human
monoclonal CAT-192 κ -chain, dimer

p. 258 **paliferminum**
palifermin

replace the description and the graphic formula by the following:
human fibroblast growth factor-(24-163)-peptide

palifermine

remplacer la description et la formule développée par la suivante:
peptide-(24-163)-facteur de croissance du fibroblaste humain

palifermina

sustitúyase la descripción y la fórmula empírica por la siguiente:
péptido-(24-163)-factor de crecimiento del fibroblasto humano

SYDMEG GDIRVRLFC
RTQWYLRIDK RGKVKGQTQEM KNNYNIMEIR TVAVGIVAIAK
GVESEFYLAM NKEGKLYAKK ECNEDCNFKE LILENHNTY
ASAKWTHNGG EMFVALNQKG IPVRGKTKK EQKTAHFLPM
AIT

p. 267 *delete/supprimer/suprimase*

insert/insérer/insértese

pittrakinraum

pittrakinrum

Procedure and Guiding Principles / Procédure et Directives / Procedimientos y principios generales

The text of the *Procedures for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances* and *General Principles for Guidance in Devising International Nonproprietary Names for Pharmaceutical Substances* will be reproduced in uneven numbers of proposed INN lists only.

Les textes de la *Procédure à suivre en vue du choix de dénominations communes internationales recommandées pour les substances pharmaceutiques* et des *Directives générales pour la formation de dénominations communes internationales applicables aux substances pharmaceutiques* seront publiés seulement dans les numéros impaires des listes des DCIs proposées.

El texto de los *Procedimientos de selección de denominaciones comunes internacionales recomendadas para las sustancias farmacéuticas* y de los *Principios generales de orientación para formar denominaciones comunes internacionales para sustancias farmacéuticas* aparece solamente en los números impares de las listas de DCI propuestas.

SELECTED WHO PUBLICATIONS OF RELATED INTEREST

WHO Expert Committee on Biological Standardization

Fiftieth Report

WHO Technical Report Series, No. 904

2002 (107 pages)

Sw.fr. 23.-

WHO Expert Committee on Drug Dependence

Thirty-second report

WHO Technical Report Series, No. 903

2002 (v + 26 pages)

Sw.fr. 14.-

The selection and use of essential medicines

Report of the WHO Expert Committee

(including the revised Model List of Essential Medicines)

WHO Technical Report Series, No. 914

2003 (61 pages)

Sw.fr. 23.-

Quality control methods for medicinal plant materials

1998 (115 pages)

Sw.fr. 35.-

**Quality assurance of pharmaceuticals. A compendium
of guidelines and related materials. Volume 1.**

1997 (238 pages)

Sw.fr. 50.-

**Quality assurance of pharmaceuticals. A compendium
of guidelines and related materials. Volume II.**

1999 (196 pages)

Sw.fr. 62.-

WHO Model Formulary

2002 (500 pages)

Sw.fr. 36.-

Specifications for pharmaceutical preparations

Thirty-seventh report of the WHO Expert Committee

WHO Technical Report Series, No. 908

2003 (viii + 136 pages)

Sw.fr. 25.-

**Basic tests for drugs: pharmaceutical substances,
medicinal plant materials and dosage forms**

1998 (iii + 91 pages)

Sw.fr. 26.-

**International Nonproprietary Names (INN)
for Pharmaceutical Substances, CD-ROM**

2002

Sw.fr. 290.-

Further information on these and other World Health Organization publications can be obtained from
Distribution and Sales, World Health Organization, 1211 Geneva 27, Switzerland.
<http://www.who.int/dsa>

This material was copied
at the NLM and may be
Subject US Copyright Laws

varespladibum

varespladib

[[3-(aminooxoacetyl)-1-benzyl-2-ethyl-1*H*-indol-4-yl]oxy]acetic acid

varespladib

acide [[3-(aminooxoacétyl)-1-benzyl-2-éthyl-1*H*-indol-4-yl]oxy]acétique

varespladib

ácido [[3-(aminooxoacetil)-1-bencil-2-etil-1*H*-indol-4-il]oxi]acético $C_{21}H_{23}N_2O_5$ 